News

CITI Program Content is Current with New FDA Guidance

On 24 July 2017, the U.S. FDA issued guidance that it will not object if an IRB approves a waiver or alteration of consent for a no more than minimal risk clinical investigation.

Learn More
CITI Program Content is Current with New FDA Guidance

Recent News

CITI Program GCP Training ICH E6(R2) New Course Available: GCP for Social & Behavioral Research Module Retirement for HSR GLP and HEC Promotional Offer New Disaster and Conflict Research Modules April 2017 Newsletter New Data and Safety Monitoring Module Recently Added sIRB Modules Recently Added EC Modules Updated GCP Modules - New ICH E6(R2) Integrated Addendum January 2017 Newsletter Test Drive the New NIH IND/IDE Template in Protocol Builder® Important Notification of Rate Increase New Modules: Clinical Trial Agreement (CTA) CITI Program GCP Training Complies with NIH Policy New Module: Informed Consent and Incidental Findings in Research with Human Subjects Special pricing on Protocol Builder® for our Institutional Subscribers